Key result
Impella shows no significant difference in bleeding over IABP during VA-ECMO despite lower mortality.
Why the study?
Adjunctive LV unloading strategies during VA-ECMO for refractory cardiogenic shock include IABP and Impella, but their comparative outcomes remain unclear.
Does Impella compared with IABP for left ventricular unloading during VA-ECMO alter clinically significant bleeding and mortality in adults with refractory cardiogenic shock?
Meta-Analysis (n=592)
nonrandomized treatment allocation (all included studies were retrospective)
Does Impella compared with IABP for left ventricular unloading during VA-ECMO alter clinically significant bleeding and mortality in adults with refractory cardiogenic shock?
In retrospective comparisons of LV unloading during VA-ECMO, Impella is associated with higher rates of CNS and access-site bleeding than IABP but lower pooled 30-day mortality, highlighting the need for prospective randomized trials.
Answers are grounded in this paper and cite their sources.
No significant difference in clinically significant bleeding; observational data leave open optimal LV unloading choice in VA-ECMO.
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is used for refractory cardiogenic shock, but retrograde aortic flow increases left ventricular (LV) afterload, impairing myocardial recovery. Adjunctive unloading strategies, including intra-aortic balloon pump (IABP) and Impella, are commonly employed, though comparative outcomes remain unclear. We performed a systematic review and meta-analysis of studies comparing Impella versus IABP for LV unloading during VA-ECMO in adults. Databases were searched through January 15, 2026. The primary outcome was clinically significant bleeding. Secondary outcomes included CNS hemorrhage, access-site bleeding, renal replacement therapy (RRT), and mortality. Random-effects models were used to calculate pooled risk ratios (RR) with 95% confidence intervals (CI). Seven retrospective studies ( n = 592; Impella 250, IABP 342) were included. 6 studies contributed data to the primary bleeding analysis (Impella N = 221; IABP n = 314). Clinically significant bleeding or author reported bleeding occurred in 58.8% of Impella-treated patients and 37.6% of IABP treated patients (RR 1.44, 95% CI 0.93–2.24; I²=90%), though not statistically significant. Impella was associated with increased CNS hemorrhage (RR 3.64, 95% CI 1.32–10.07) and access-site bleeding (RR 1.94, 95% CI 1.11–3.41). Gastrointestinal bleeding did not differ significantly between groups (RR 1.58, 95% CI 0.65–3.84), nor did Renal Replacement Therapy (RR 1.27, 95% CI 0.89–1.80). In-hospital mortality did not differ (RR 0.98, 95% CI 0.71–1.37), while pooled 30-day mortality was lower in the Impella cohorts (RR 0.79, 95% CI 0.64–0.99). Available retrospective comparative data suggest that Impella based LV unloading during VA-ECMO is associated with higher rates of selected bleeding complications, particularly CNS and access-site hemorrhage, while pooled 30-day mortality favored Impella use. All studies were retrospective with nonrandomized treatment allocation and therefore findings should be interpreted as hypothesis generating rather than causal. Prospective studies with standardized bleeding and anticoagulation reporting are needed to define the optimal unloading strategy during VA-ECMO.
No takes yet. Share an insight, caveat, or question.
Bartlett et al. (2026) conducted a meta-analysis in Refractory cardiogenic shock requiring VA-ECMO with left ventricular unloading (n=592). Impella for left ventricular unloading during VA-ECMO vs. Intra-aortic balloon pump (IABP) for left ventricular unloading during VA-ECMO was evaluated on Clinically significant bleeding or author-reported bleeding (RR 1.44, 95% CI 0.93-2.24). Impella versus IABP for LV unloading during VA-ECMO showed no significant difference in primary bleeding but reduced 30-day mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: